Status:
COMPLETED
Buprenorphine in the Treatment of Osteoarthritis (OA) in the Elderly
Lead Sponsor:
Napp Pharmaceuticals Limited
Conditions:
Osteoarthritis
Eligibility:
All Genders
65+ years
Phase:
PHASE4
Brief Summary
The primary objective is to compare buprenorphine transdermal delivery system (BTDS) with standard- treatment in subjects with osteoarthritis (OA).
Eligibility Criteria
Inclusion
- Either sex aged 65 or above
- Diagnosis of OA of the hip and/or knee
- Severe pain requiring step two medication
- Taking maximum dose of paracetamol
Exclusion
- Painful disease of the joints other than OA
- Contraindication to buprenorphine, other opioids, patch adhesives or nonsteroidal anti-inflammatory agents (NSAIDS)
- Subjects taking cyclooxygenase (COX) II selective inhibitors
Key Trial Info
Start Date :
March 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2007
Estimated Enrollment :
219 Patients enrolled
Trial Details
Trial ID
NCT00324038
Start Date
March 1 2006
End Date
December 1 2007
Last Update
June 14 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Napp Pharmaceuticals Ltd
Cambridge, United Kingdom, CB4 0GW